ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 80 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,580,590 | -12.2% | 1,436,900 | -1.0% | 0.00% | 0.0% |
Q1 2024 | $1,799,364 | +20.6% | 1,451,100 | +2.1% | 0.00% | +33.3% |
Q4 2023 | $1,492,050 | +49.2% | 1,421,000 | +873.3% | 0.00% | 0.0% |
Q3 2023 | $1,000,100 | +296.9% | 146,000 | +500.8% | 0.00% | +200.0% |
Q2 2023 | $251,991 | -23.1% | 24,300 | -40.0% | 0.00% | 0.0% |
Q1 2023 | $327,645 | +69.8% | 40,500 | +204.5% | 0.00% | – |
Q4 2021 | $193,000 | -34.6% | 13,300 | -18.9% | 0.00% | -100.0% |
Q3 2021 | $295,000 | -77.0% | 16,400 | -77.6% | 0.00% | -66.7% |
Q2 2021 | $1,285,000 | -15.5% | 73,200 | +21.4% | 0.00% | -25.0% |
Q1 2021 | $1,520,000 | +398.4% | 60,300 | +27.8% | 0.00% | +300.0% |
Q4 2020 | $305,000 | +408.3% | 47,200 | +103.4% | 0.00% | – |
Q3 2020 | $60,000 | +42.9% | 23,200 | -10.4% | 0.00% | – |
Q2 2020 | $42,000 | +16.7% | 25,900 | -25.4% | 0.00% | – |
Q1 2020 | $36,000 | -67.0% | 34,700 | -40.1% | 0.00% | – |
Q4 2019 | $109,000 | -34.7% | 57,900 | -62.6% | 0.00% | – |
Q3 2019 | $167,000 | – | 155,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 3,399,034 | $49,422,000 | 10.17% |
VR Adviser, LLC | 4,563,962 | $66,360,000 | 9.07% |
COMMODORE CAPITAL LP | 2,672,346 | $38,856,000 | 9.00% |
TCG Crossover Management, LLC | 1,082,213 | $15,735,000 | 7.37% |
Foresite Capital Management V, LLC | 1,258,243 | $18,295,000 | 4.50% |
Parkman Healthcare Partners LLC | 1,025,522 | $14,911,000 | 3.29% |
Aisling Capital Management LP | 634,455 | $9,225,000 | 3.25% |
GREAT POINT PARTNERS LLC | 800,000 | $11,632,000 | 2.58% |
Samsara BioCapital, LLC | 794,171 | $11,547,000 | 2.24% |
Affinity Asset Advisors, LLC | 400,000 | $5,816,000 | 2.11% |